Molecular testing has become a mandatory component of the non-small cell lung cancer
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …

Lung cancer remains the leading cause of cancer-related death. In addition to chest X-rays
and computerised tomography, the detection of cancer biomarkers serves as an emerging …

Gene fusions have a pivotal role in non-small cell lung cancer (NSCLC) precision medicine.
Several techniques can be used, from fluorescence in situ hybridization and …

Cancer of unknown primary has a dismal prognosis, especially following failure of platinum-
based chemotherapy. 10-20% of patients have a high tumor mutational burden (TMB), which …

Objectives An increasing number of treatment-determining biomarkers has been identified in
non-small cell lung cancer (NSCLC) and molecular testing is recommended to enable …

Lung cancer is a highly heterogeneous disease often driven by well-characterized driver
mutations. Although the best studied are common alterations in the epidermal growth factor …

Simple Summary Non-Small-Cell Lung Cancer (NSCLC) is the primary cause of cancer-
related death worldwide. Patients carrying Epidermal Growth Factor Receptor (EGFR) …

Next‐generation sequencing has become a cornerstone of therapy guidance in cancer
precision medicine and an indispensable research tool in translational oncology. Its rapidly …

Immunotherapies have recently gained traction as highly effective therapies in a subset of
late-stage cancers. Unfortunately, only a minority of patients experience the remarkable …

Introduction PD-(L) 1 inhibitors have improved prognosis of non-small-cell lung cancer
(NSCLC), but can also cause immune-related adverse events (irAEs) that complicate …